Abstract
Streptococcus pneumoniae is a leading cause of bacteremia, sepsis, meningitis, pneumonia, sinusitis, and acute otitis media in young children. Some serotypes are associated with particular disease syndromes, such as complicated pneumonias in children, or with higher rates of hospitalization in children and are consistently responsible for outbreaks in certain populations. In this report we describe a case of a nine-year-old boy who developed an abscess of pleura and invasive pneumococcal bacteremia. The boy was admitted to the hospital with abdominal pain and vomiting, accompanied by mild cough and fever. Chest X-ray revealed lower left lobe consolidation with pleural inflammation and chest CT showed extensive interstitial-alveolar changes in the left lung with atelectasis and pleural effusion causing a reduction in lung volume up to the fourth rib. From the 6th day of hospitalization on, suction drainage and intrapleural administration of alteplase were continued for 5 days. Intravenous antibiotics were administered for subsequent 32 days. The course of disease was complicated with labial herpes and acute adenoviral gastroenteritis. The costs of diagnosis (11.7%), pharmacotherapy (55.2%), hospitalization (30.7%) and additional procedures (2.4%) were about €4,444, while the cost of treatment from the perspective of the National Health Fund was only €1,508. The costs of treating the boy with sepsis caused by S. pneumoniae serotype 1 were thus about three times higher than those from the perspective of providers of the National Health Fund. Administration of a new pneumococcal conjugated vaccine containing serotype 1 (PHiD-CV10 or PCV13) could have prevented invasive pneumococcal disease in the described patient.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Advisory Committee on Immunisation Practices. (2000). Preventing pneumococcal disease among infants and young children: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and Reports, 45((RR-9)), 1–35.
American Academy of Pediatrics. (2000). Policy statement: Recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics, 106, 362–366.
Bergman, A., Hjelmgren, J., Ortqvist, A., Wisløff, T., Kristiansen, I. S., Högberg, L. D., Persson, K. M., & Persson, U. (2008). Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden. Scandinavian Journal of Infectious Diseases, 40(9), 721–729.
Beutels, P., Van Damme, P., & Osterhuis-Kafeja, F. (2006). Effects and costs of pneumococcal conjugate vaccination of Belgian children. KCE reports, 33C. Belgian Health Care Knowledge Centre. Retrieved on July 2, 2011, from http://www.kce.fgov.be/index_en.aspx?SGREF=5220
CDC. (2008). Updated Recommendation from the Advisory Committee on Immunisation Practices (ACIP) for use of 7-valent pneumococcal conjugate vaccine (pcv7) in children aged 24-59 months who are not completely vaccinated. MMWR Weekly, 57(13), 343–344.
Centers for Disease Control and Prevention. (2000). Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and Reports, 49(RR-9), 1–38.
Claes, C., Reinert, R. R., & der Schulenburg, J. M. (2009). Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects. The European Journal of Health Economics, 10(1), 25–38.
Ess, S. M., Schaad, U. B., Gervaix, A., Pinosch, S., & Szucs, T. D. (2003). Cost-effectiveness of a pneumococcal conjugate immunisation program for infants in Switzerland. Vaccine, 21(23), 3273–3281.
European Central Bank. (2011). Eurosystem. Euro exchange rates. Retrieved on July 2, 2011, from http://www.ecb.int/stats/exchange/eurofxref/html/eurofxref-graph-gbp.en.html
Grzesiowski, P., Skoczynska, A., Albrecht, P., Konior, R., Patrzałek, M., Sadowska, M., Staroszczyk, J., Szenborn, L., Wysocki, J., Hryniewicz, W., & Polish Pediatric IPD Group. (2008). Invasive pneumococcal disease in children up to 5 years of age in Poland. European Journal of Clinical Microbiology & Infectious Diseases, 27(9), 883–885.
Hamblin, S. E., & Furmanek, D. L. (2010). Intrapleural tissue plasminogen activator for the treatment of parapneumonic effusion. Pharmacotherapy, 30(8), 855–862.
Hausdorff, W. P. (2007). The roles of pneumococcal serotypes 1 and 5 in pediatric invasive disease. Vaccine, 25, 2406–2412.
Hausdorff, W. P., Bryant, J., Paradiso, P. R., & Siber, G. R. (2000). Which pneumococcal serogroups cause the most invasive disease: Implications for conjugate vaccine formulation and use, Part I. Clinical Infectious Diseases, 30, 100–121.
Hawkins, J. A., Scaife, E. S., Hillman, N. D., & Feola, G. P. (2004). Current treatment of pediatric empyema. Seminars in Thoracic and Cardiovascular Surgery, 16(3), 196–200.
Jackowska, T., & Kłyszewska, M. (2010). Implementation of the recommended vaccinations for children and assessment of awareness of their parents. Pediatria Polska, 85(3), 201–206 (Article in Polish).
Koegelenberg, C. F. N., Diacon, A. H., & Bolliger, C. T. (2008). Parapneumonic pleural effusion and empyema. Respiration, 75, 241–250.
Marchetti, M., & Colombo, G. L. (2005). Cost-effectiveness of universal pneumococcal vaccination for infants in Italy. Vaccine, 23(37), 4565–4576.
McIntosh, E. D., Conway, P., Willingham, J., & Lloyd, A. (2003). The cost-burden of paediatric pneumococcal disease in the UK and the potential cost-effectiveness of prevention using 7-valent pneumococcal conjugate vaccine. Vaccine, 21(19–20), 2564–2572.
National Health Fund. (2011). Catalogue of diagnosed related group (JGP). Poland: National Health Fund (NFZ). Retrieved on July 2, 2011, from http://www.nfz.gov.pl
OECD. (2011). StatExtracts. Consumer price index. Retrieved on July 2, 2011, from http://stats.oecd.org/Index.aspx?DataSetCode=MEI_PRICES
OECD. (2011). StatExtracts. Purchasing power parities. Retrieved on July 2, 2011, from http://stats.oecd.org/Index.aspx?DataSetCode=MEI_PRICES
Rozenbaum, M. H., Sanders, E. A., van Hoek, A. J., Jansen, A. G., van der Ende, A., van den Dobbelsteen, G., Rodenburg, G. D., Hak, E., & Postma, M. J. (2010). Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the 7-valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. British Medical Journal, 340, c2509.
Ruckinger, S., von Kries, R., Siedler, A., & van der Linden, M. (2009). Association of serotype of Streptococcus pneumoniae with risk of severe and fatal outcome. Pediatric Infectious Disease Journal, 28, 118–122.
Salo, H., Sintonen, H., Nuorti, J. P., Linna, M., Nohynek, H., Verho, J., & Kilpi, T. (2005). Economic evaluation of pneumococcal conjugate vaccination in Finland. Scandinavian Journal of Infectious Diseases, 37(11–12), 821–832.
Skoczynska, A., Sadowy, E., Bojarska, K., Strzelecki, J., Kuch, A., Gołębiewska, A., Wasko, I., Forys, M., van der Linden, M., & Hryniewicz, W. (2011). Participants of laboratory-based surveillance of community acquired invasive bacterial infections (BINet). The current status of invasive pneumococcal disease in Poland. Vaccine, 29(11), 2199–2205.
Sulikowska, A., Grzesiowski, P., Sadowy, E., Fiett, J., & Hryniewicz, W. (2004). Characteristics of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolated from the nasopharynges of asymptomatic children and molecular analysis of S. pneumoniae and H. influenzae strain replacement in the nasopharynx. Journal of Clinical Microbiology, 42, 3942–3949.
Williams, B. G., Gouws, E., Boschi-Pinto, C., Bryce, J., & Dye, C. (2002). Estimates of world-wide distribution of child deaths from acute respiratory infections. The Lancet Infectious Diseases, 2, 25–32.
Wisloff, T., Abrahamsen, T. G., Bergsaker, M. A., Løvoll, Ø., Møller, P., Pedersen, M. K., & Kristiansen, I. S. (2006). Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program. Vaccine, 24(29–30), 5690–5699.
Acknowledgements
Supported by CMKP grant 501-1-1-19-42/2009.
Conflicts of interest: The authors declare no conflicts of interest in relation to this article.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media Dordrecht
About this paper
Cite this paper
Jackowska, T., Zaleska-Ponganis, J., Dziurda, D. (2013). Invasive Pneumococcal Bacteremia in a 9-Year-Old Boy Caused by Serotype 1: Course, Treatment and Costs. In: Pokorski, M. (eds) Respiratory Regulation - Clinical Advances. Advances in Experimental Medicine and Biology, vol 755. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-4546-9_33
Download citation
DOI: https://doi.org/10.1007/978-94-007-4546-9_33
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-4545-2
Online ISBN: 978-94-007-4546-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)